Poxel’s Diabetes Drug Wins Japan Nod, But Competition Remains Fierce
As French biotech Poxel marks the first market approval of its oral type 2 diabetes…
As French biotech Poxel marks the first market approval of its oral type 2 diabetes…
Lyon is one of the hotspots for biotech in Europe. Here are 10 of the…
An oral first-in-class drug targeting the mitochondria, developed by the French biotech Poxel, has shown…
Update (13/03/2018): Poxel has started two more Phase III trials in Japan testing its drug…
Swiss pharma Roivant has given French biotech Poxel €28M upfront to get involved with the development…
Try as we might, we can't cover all the biotech news out there. During the…
Poxel has closed a capital increase on the Euronext Paris, raising €26.5M. The money is…
Poxel, the French company that made a €27M IPO last February, announced the successful conclusion…
Poxel continues to interest the market after its successful IPO in February 2015, where it…